RDNT

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended January 31, 1998, for Primedex Health Systems, Inc. (Note: The filing metadata lists "Radnet, Inc.", but the document text identifies the registrant as Primedex Health Systems, Inc., which operates Radnet as a primary subsidiary). The company operates diagnostic imaging centers and related services. The financial statements are unaudited and reflect the consolidation of Radnet, Primedex Health Systems (PHS), Radnet Managed Imaging Services (RMIS), and Diagnostic Imaging Services (DIS).

Key Financial Metrics

Note: Total Debt calculated as sum of Notes/Leases Payable (Current & Long-Term) and Subordinated Debentures Payable.

Material Changes vs. Prior Period

• Improved Operating Performance: Operating loss decreased significantly from $5.19 million in Q1 1997 to $0.51 million in Q1 1998. This improvement is primarily due to the absence of a $4.95 million impairment loss recorded in the prior year related to the closure of the Parkside facility.
• Revenue Decline: Net revenue decreased by approximately 19% ($3.37 million) year-over-year. This was driven by the sale of DIS's Ultrasound Division and MRI facilities to Diagnostic Health Services, Inc. (DHS), the sale of Future Diagnostics, Inc. (FDI), and the closure of Parkside.
• Divestitures and Sales:
  • Sold interest in Scripps Chula Vista MRI (SCV) to DHS for DHS stock (valued at $1.43 million).
  • Dissolved partnership with Friendly Hills Healthcare Network, resulting in write-offs of receivables and property but a small gain on dissolution.
• Debt Reduction: The company repurchased approximately $1.1 million of subordinated bond debentures, resulting in an extraordinary gain of $589,122 from early extinguishment of debt.
• Accounting Change: Adoption of SOP 98-5 resulted in a $780,000 write-off of start-up costs, increasing the net loss.

Outlook, Risks, and Contingencies

• Liquidity Concerns: The company reported a working capital deficit of approximately $14.1 million. Liquidity is maintained through two lines of credit totaling up to $14 million (with $11.2 million outstanding as of Jan 31, 1998), secured by accounts receivable and personal guarantees from the CEO.
• Debt Obligations: Significant future debt payments are scheduled, totaling approximately $29.8 million in the first year of the next five-year period (assuming lines of credit are paid in year one).
• Operational Consolidation: The company plans to consolidate three Tower locations into a new Beverly Hills facility in fiscal 1999 to reduce rental costs by approximately $1 million annually, though there is a risk of volume loss during the transition.
• Subsequent Events:
  • Received $1.5 million in DHS stock for post-closing payments on the MRI sale, subsequently sold for a gain of ~$534,000.
  • Sold DHS stock received from the SCV transaction for a loss of ~$200,000.
  • Continued repurchase of subordinated debentures post-quarter.
• Litigation: A class action lawsuit ("In re Hibbard Brown & Company Securities Litigation") remains pending, though a preliminary settlement of $240,000 was reached in 1996 and management expects no additional costs.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the two primary lines of credit, which are secured by receivables and require personal guarantees from the CEO.
• Working Capital Deficit: Assess the sustainability of operations given the $14.1 million working capital deficit and heavy reliance on revolving credit.
• Revenue Concentration: Confirm the impact of the divestitures (DIS MRI/Ultrasound, FDI, Parkside) on long-term revenue stability versus the reported short-term decline.
• Related Party Transactions: Review the $1 million loan to the CEO and other officer loans/loans to related parties disclosed in the notes.
• Stock Ownership: Verify the company's increasing ownership stake in Diagnostic Imaging Services (DIS), which reached approximately 75% as of May 1998.